Skip to main content

Advertisement

Contact Ki Cheong Park

From: SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

Contact corresponding author